Golotimod

Research use only, not for human use.

Golotimod (SCV 07) is an antimicrobial dipeptide with immunomodulatory activity that significantly improves the efficacy of anti-tuberculosis therapy.

Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).

——

Golotimod (SCV-07) (oral gavage or subcutaneous injection, 100 μg/kg, 5 days) reduces experimental recurrent genital HSV-2 disease by oral administration, more importantly, oral SCV07 after fasting shows a greater reduction in incidence and severity than SCV-07 without fasting in female hartley guinea pigs.Golotimod (SCV-07) (subcutaneous injection, once or twice a day from days 1 to 20, 100 μg/kg) can reduce the severity and duration of acute and split radiation-induced oral mucositis (OM) and short the duration of ulcerative OM in male LVG golden Syrian Hamsters.Animal Model:Female Hartley guinea pigs (250-300 g) infected HSV-2Dosage:100 μg/kg Administration:Oral gavage or subcutaneous injection; 5 days Result:Reduced incidence of lesions from 55% (one week before treatment) to only 18% by oral administration, and showed no significant reduction in disease by subcutaneous injection of SCV-07.Animal Model:Male LVG golden Syrian Hamsters weighing approximately 80 g with radiation-induced mucositis Dosage:10, 100 μg/kg or 1 mg/kg Administration: Subcutaneous injection; once or twice a day from days 1 to 20 Result:Showed a peak mucositis of 3.0 on day 18 in the control group compared to only 2.2 in the test group, and the mucositis score in the SCV-07 treated hamsters was only 6.3% compared to 28.1% in the control group at dose of 100 μg/kg.Significantly decreased the severity and duration of oral mucositis (OM) at dose of 10 μg/kg, 100 μg/kg or 1 mg/kg.

——

Microbiology/Virology

Antibiotic

Antibiotic

——

——

229305-39-9

333.34

C16H19N3O5

>98% (HPLC)

In Vitro:?H2O : 125 mg/mL (374.99 mM; Ultrasonic)

[H][C@@](N)(CCC(=O)N[C@@]([H])(Cc1c[nH]c2ccccc12)C(O)=O)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years